|
JP4334866B2
(ja)
|
2000-10-09 |
2009-09-30 |
アイシス イノヴェイション リミテッド |
治療用抗体
|
|
ES2628395T3
(es)
|
2007-08-15 |
2017-08-02 |
Bayer Pharma Aktiengesellschaft |
Anticuerpo regulado por proteasa
|
|
AU2013202755B2
(en)
*
|
2007-08-22 |
2016-05-12 |
Cytomx Therapeutics, Inc. |
Activatable binding polypeptides and methods of identification and use thereof
|
|
CA3128656A1
(en)
|
2007-08-22 |
2009-02-26 |
The Regents Of The University Of California |
Activatable binding polypeptides and methods of identification and use thereof
|
|
AU2016213702C1
(en)
*
|
2007-08-22 |
2018-11-29 |
Cytomx Therapeutics, Inc. |
Activatable binding polypeptides and methods of identification and use thereof
|
|
CN102482347B
(zh)
|
2009-01-12 |
2017-04-26 |
希托马克斯医疗有限责任公司 |
修饰抗体组合物及其制备和使用方法
|
|
RU2011138951A
(ru)
|
2009-02-23 |
2013-03-27 |
Сайтомкс Терапьютикс, Инк. |
Пропротеины и способы их применения
|
|
CA2871458C
(en)
|
2012-04-27 |
2020-06-23 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
|
WO2013177596A2
(en)
|
2012-05-25 |
2013-11-28 |
Sloan Kettering Institute For Cancer |
Methods for treating gi syndrome and graft versus host disease
|
|
US9856314B2
(en)
|
2012-06-22 |
2018-01-02 |
Cytomx Therapeutics, Inc. |
Activatable antibodies having non-binding steric moieties and methods of using the same
|
|
EP2863948B1
(en)
|
2012-06-22 |
2018-10-24 |
Cytomx Therapeutics Inc. |
Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
|
|
WO2014052462A2
(en)
|
2012-09-25 |
2014-04-03 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
|
|
AU2014204015A1
(en)
|
2013-01-04 |
2015-07-09 |
Cytomx Therapeutics, Inc. |
Compositions and methods for detecting protease activity in biological systems
|
|
US10633453B2
(en)
|
2013-05-28 |
2020-04-28 |
Kaohsiung Medical University |
Antibody locker for the inactivation of protein drug
|
|
US9517276B2
(en)
|
2013-06-04 |
2016-12-13 |
Cytomx Therapeutics, Inc. |
Compositions and methods for conjugating activatable antibodies
|
|
HRP20220553T1
(hr)
|
2013-07-25 |
2022-06-10 |
Cytomx Therapeutics Inc. |
Polispecifična protutijela, polispecifična protutijela koja se mogu aktivirati i postupci uporabe navedenih protutijela
|
|
US20150087810A1
(en)
|
2013-09-25 |
2015-03-26 |
Cytomx Therapeutics, Inc. |
Matrix Metalloproteinase Substrates And Other Cleavable Moieties And Methods Of Use Thereof
|
|
US9540440B2
(en)
|
2013-10-30 |
2017-01-10 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
|
WO2015089283A1
(en)
|
2013-12-11 |
2015-06-18 |
Cytomx Therapeutics, Inc. |
Antibodies that bind activatable antibodies and methods of use thereof
|
|
BR112016017649B1
(pt)
|
2014-01-31 |
2024-01-30 |
Cytomx Therapeutics, Inc |
Polipeptídeo isolado compreendendo substratos de matriptase e de ativador do plasminogênio u e outras porções cliváveis, composição farmacêutica compreendendo o dito polipeptídeo, bem como métodos para produzir e fabricar um polipeptídeo isolado compreendendo uma porção clivável e uso da composição farmacêutica e quantidade terapeuticamente eficaz da dita composição no tratamento de um distúrbio ou doença
|
|
WO2016014974A2
(en)
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
|
MA41374A
(fr)
|
2015-01-20 |
2017-11-28 |
Cytomx Therapeutics Inc |
Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
|
|
WO2016149201A2
(en)
|
2015-03-13 |
2016-09-22 |
Cytomx Therapeutics, Inc. |
Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
|
|
SG10201913762QA
(en)
|
2015-05-04 |
2020-03-30 |
Cytomx Therapeutics Inc |
Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof
|
|
CN107849133B
(zh)
|
2015-05-04 |
2022-08-23 |
西托姆克斯治疗公司 |
抗cd166抗体、可活化抗cd166抗体及其使用方法
|
|
US10233244B2
(en)
|
2015-05-04 |
2019-03-19 |
Cytomx Therapeutics, Inc. |
Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and methods of use thereof
|
|
BR112018000768A2
(pt)
|
2015-07-13 |
2018-09-25 |
Cytomx Therapeutics Inc |
anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos
|
|
CA3042679A1
(en)
|
2016-11-03 |
2018-05-11 |
Bristol-Myers Squibb Company |
Activatable anti-ctla-4 antibodies and uses thereof
|
|
EA201991353A1
(ru)
|
2016-12-09 |
2019-11-29 |
|
Двухвалентные антитела, маскированные спирализованными спиралями
|
|
CN110914302A
(zh)
|
2017-06-01 |
2020-03-24 |
赛托姆克斯治疗学股份有限公司 |
可活化抗pdl1抗体及其使用方法
|
|
JP2020531045A
(ja)
|
2017-07-14 |
2020-11-05 |
シートムエックス セラピューティクス，インコーポレイテッド |
抗ｃｄ１６６抗体およびその使用
|
|
AU2018304711B2
(en)
|
2017-07-20 |
2025-04-10 |
Cytomx Therapeutics, Inc. |
Methods of qualitatively and/or quantitatively analyzing properties of activatable antibodies and uses thereof
|
|
EP3668545A2
(en)
|
2017-08-16 |
2020-06-24 |
Bristol-Myers Squibb Company |
Prodruggable antibodies, prodrugs thereof, and methods of use and making
|
|
IL321773A
(en)
|
2017-10-14 |
2025-08-01 |
Cytomx Therapeutics Inc |
Activatable antibodies and methods for preparing them
|
|
CN120248140A
(zh)
|
2018-12-06 |
2025-07-04 |
西托姆克斯治疗公司 |
基质金属蛋白酶可裂解的和丝氨酸或半胱氨酸蛋白酶可裂解的底物及其使用方法
|
|
WO2020247572A1
(en)
|
2019-06-05 |
2020-12-10 |
Seattle Genetics, Inc. |
Masked antibody formulations
|
|
AR119097A1
(es)
|
2019-06-05 |
2021-11-24 |
Seattle Genetics Inc |
Métodos de purificación de anticuerpos enmascarados
|
|
US20220251206A1
(en)
|
2019-06-11 |
2022-08-11 |
Bristol-Myers Squibb Company |
Anti-ctla4 antibody prodruggable (probody) at a cdr position
|
|
KR20220166814A
(ko)
|
2020-04-09 |
2022-12-19 |
싸이톰스 테라퓨틱스, 인크. |
활성화 가능한 항체를 함유하는 조성물
|
|
MX2022012592A
(es)
|
2020-04-10 |
2022-12-07 |
Cytomx Therapeutics Inc |
Construcciones de citocinas activables y composiciones y metodos relacionados.
|
|
MX2023010840A
(es)
|
2021-03-16 |
2023-10-26 |
Cytomx Therapeutics Inc |
Construcciones de citocinas activables enmascaradas y composiciones y métodos relacionados.
|
|
US20240352080A1
(en)
|
2021-07-14 |
2024-10-24 |
Seagen Inc. |
Antibody Masking Domains
|
|
EP4405387A1
(en)
|
2021-09-24 |
2024-07-31 |
Seagen Inc. |
Improved antibody masking domains
|
|
US20250136717A1
(en)
|
2022-05-16 |
2025-05-01 |
Byondis B.V. |
Novel masked antibodies
|